Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
SALT LAKE CITY, Aug. 7 2023 – Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight® Psychotropic test, a pharmacogenomic test for…
Read More